RKDA

MKT CAP:$1M

Arcadia Biosciences, Inc.

Market Cap

$1M

Basic Materials·Agricultural Inputs·🇺🇸 United States·NASDAQ

Materials·Agricultural·🇺🇸·NASDAQ

Stock Price

$1.12-$1.03 (-47.91%)

Apr 22, 2026

Company Details

Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in t...

CEO

Thomas J. Schaefer

IPO Date

May 15, 2015

Website

www.arcadiabio.com

Key Metrics TTM

Revenue

$5M

-8.8% YoY

Net Income

-$2M

EPS (Diluted)

-$1.72

Free Cash Flow

-$5M

Revenue / Share

$3.55

Gross Margin

36.2%

Operating Margin

-51.4%

Net Margin

-48.1%

FCF Margin

-97.6%

P/S

0.3x

P/E

—

Earnings Reports

Q1 2026

May 7, 2026

PENDING

FY 2025

Mar 26, 2026

$5MEPS -$1.71

Q4 2025

Mar 26, 2026

$901.0K-25.9%EPS -$0.98

Q3 2025

Nov 7, 2025

$1MEPS $0.62

Q2 2025

Aug 14, 2025

$1M+11.4%EPS -$3.26

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 18	$370.0K	$246.0K	-$4M
Q4 18	$444.0K	$214.0K	-$4M
Q1 19	$158.0K	$99.0K	-$4M
Q2 19	$203.0K	$114.0K	-$5M
Q3 19	$392.0K	$215.0K	-$6M
Q2 20	$281.0K	-$1M	-$7M
Q3 20	$314.0K	-$2M	-$8M
Q2 21	$1M	-$182.0K	-$8M
Q3 22	$2M	$442.0K	-$4M
Q1 23	$1M	$544.0K	-$4M
Q2 24	$1M	$673.0K	$2M
Q4 24	$1M	$389.0K	-$2M
Q1 25	$1M	$518.0K	$530.0K
Q2 25	$1M	$631.0K	-$501.0K
Q3 25	$1M	$418.0K	-$1M
Q4 25	$901.0K	$192.0K	-$1M

Valuation

Quarter	P/S	P/E
Q3 18	373.9x	—
Q4 18	10.3x	—
Q1 19	26.2x	—
Q2 19	18.5x	—
Q3 19	1353.0x	—
Q2 20	35.4x	—
Q3 20	24.8x	—
Q2 21	28.2x	—
Q3 22	3.8x	—
Q1 23	2.4x	—
Q2 24	0.8x	—
Q4 24	1.5x	—
Q1 25	0.8x	—
Q2 25	1.1x	—
Q3 25	0.9x	—
Q4 25	0.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 18	-$4M	-$4M
Q4 18	-$3M	-$3M
Q1 19	-$4M	-$4M
Q2 19	-$4M	-$5M
Q3 19	-$4M	-$4M
Q2 20	-$7M	-$8M
Q3 20	-$7M	-$7M
Q2 21	-$6M	-$6M
Q3 22	-$3M	-$3M
Q1 23	-$3M	-$3M
Q2 24	-$2M	-$2M
Q4 24	-$2M	-$2M
Q1 25	-$2M	-$2M
Q2 25	-$2M	-$2M
Q3 25	-$257.0K	-$257.0K
Q4 25	-$861.0K	-$861.0K

Capital Expenditures

Quarter	CapEx
Q3 18	$21.0K
Q4 18	$161.0K
Q1 19	$88.0K
Q2 19	$227.0K
Q3 19	$563.0K
Q2 20	$971.0K
Q3 20	$289.0K
Q2 21	$228.0K
Q3 22	$0
Q1 23	$0
Q2 24	$3.0K
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 18	-37.2%	+6.3%
Q4 18	-68.9%	+8.4%
Q1 19	-26.2%	+8.0%
Q2 19	-53.4%	+3.4%
Q3 19	+5.9%	+47.3%
Q2 20	-36.7%	+49.2%
Q3 20	+98.7%	+80.4%
Q2 21	+592.1%	+75.3%
Q3 22	+300.5%	-15.6%
Q1 23	+338.4%	-28.8%
Q2 24	+315.9%	-108.5%
Q4 24	-13.5%	-61.5%
Q1 25	-23.6%	-88.0%
Q2 25	+18.1%	-61.6%
Q3 25	-0.3%	+464.1%
Q4 25	-25.9%	-34.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 18	$342.0K	92.4%
Q4 18	$552.0K	124.3%
Q1 19	$422.0K	267.1%
Q2 19	$389.0K	191.6%
Q3 19	$1M	270.2%
Q2 20	$0	0.0%
Q3 20	$0	0.0%
Q2 21	$0	0.0%
Q3 22	$314.0K	20.0%
Q1 23	$212.0K	17.2%
Q2 24	$102.0K	7.8%
Q4 24	$117.0K	9.6%
Q1 25	$0	0.0%
Q2 25	$86.0K	5.9%
Q3 25	$0	0.0%
Q4 25	$17.0K	1.9%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q3 18	$1M	$3M	—
Q4 18	$2M	$3M	—
Q1 19	$2M	$3M	—
Q2 19	$2M	$3M	—
Q3 19	$2M	$4M	—
Q2 20	$2M	$4M	—
Q3 20	$2M	$4M	—
Q2 21	$1M	—	$6M
Q3 22	$255.0K	—	$4M
Q1 23	$359.0K	—	$4M
Q2 24	$10.0K	—	$3M
Q4 24	$13.0K	—	$3M
Q1 25	—	—	$2M
Q2 25	$9.0K	—	$2M
Q3 25	—	—	$2M
Q4 25	—	—	$2M

Revenue Segments

Quarter	Contract Research And Government Grants	License	Product	Royalty
Q3 18	$216.0K	$10.0K	$144.0K	—
Q1 19	$51.0K	—	$107.0K	—
Q2 19	$41.0K	—	$162.0K	—
Q3 19	$159.0K	$17.0K	$216.0K	—
Q2 20	$38.0K	—	$231.0K	$12.0K
Q3 20	$43.0K	$10.0K	$245.0K	$16.0K
Q2 21	—	—	$1M	$26.0K
Q2 24	—	—	$1M	—
Q1 25	—	—	$1M	—
Q2 25	—	—	$1M	—
Q3 25	—	—	$1M	—
Q4 25	—	—	$901.0K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$25M	$0	$25M
Q2 22	$21M	$0	$21M
Q3 22	$23M	$0	$23M
Q4 22	$21M	$0	$21M
Q1 23	$23M	$0	$23M
Q2 23	$13M	$5M	$19M
Q3 23	$11M	$5M	$16M
Q4 23	$7M	$5M	$12M
Q1 24	$3M	$5M	$9M
Q2 24	$6M	$3M	$8M
Q3 24	$4M	$3M	$7M
Q4 24	$4M	$0	$4M
Q1 25	$3M	$0	$3M
Q2 25	$1M	$3M	$4M
Q3 25	$1M	$5M	$6M
Q4 25	$259.0K	$4M	$5M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 18	119K	+44.4%	+123.8%
Q4 18	5M	+3901.5%	+118.5%
Q1 19	119K	-97.5%	+118.5%
Q2 19	126K	+5.8%	+52.8%
Q3 19	174K	+37.3%	+45.4%
Q2 20	233K	+34.3%	-95.1%
Q3 20	268K	+14.9%	+124.4%
Q2 21	544K	+102.9%	+330.2%
Q3 22	614K	+12.9%	+253.7%
Q1 23	864K	+40.8%	+270.7%
Q2 24	1M	+57.7%	+408.5%
Q4 24	1M	+0.1%	+150.9%
Q1 25	1M	+0.2%	+122.6%
Q2 25	1M	+0.1%	+58.2%
Q3 25	1M	+0.4%	+0.7%
Q4 25	1M	-0.3%	+0.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 18	$16.1K	23
Q4 18	$18.5K	24
Q1 19	$6.6K	24
Q2 19	$8.5K	24
Q3 19	$16.3K	24
Q2 20	$6.9K	41
Q3 20	$7.7K	41
Q2 21	$127.7K	11
Q3 22	$142.7K	11
Q1 23	$41.1K	30
Q2 24	$62.2K	21
Q4 24	$135.1K	9
Q1 25	$133.3K	9
Q2 25	$161.7K	9
Q3 25	$144.7K	9
Q4 25	$112.6K	8

Revenue / Employee